AstraZeneca has decided to drop the hypercholesterolemia candidate AZD8233 through to Phase III, despite meeting its Phase IIb primary efficacy endpoint, its partner Ionis announced Friday.
Rivus raised $132 million in a Series B financing round that will be used in developing HU6, a new drug class designed to treat cardio-metabolic disease by addressing obesity.
Longer-term use and early initiation of Biogen Inc.’s experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS) was effective in slowing disease progression, according to a new analysis by the company published on Wednesday.
Virios Therapeutics announced Monday its lead asset IMC-1 fell short of its primary endpoint in the Phase IIb FORTRESS study in patients with fibromyalgia.
Regeneron’s oncology strategy is to improve checkpoint inhibitor treatments with combination therapies – centered around Libtayo – according to a pipeline overview presented to investors Monday morning.
The National Institutes of Health said on Thursday it had started enrollments in a trial testing an alternative method of administering Bavarian Nordic’s monkeypox vaccine, Jynneos, which requires smaller dosages.
Bayer said on Thursday its anti-blindness treatment Eylea, jointly developed with Regeneron (REGN.O), has been shown to work as well when given at a higher dose at a longer interval between injections.
Following a favorable vote from an FDA advisory committee, Amylyx is one step closer to seeing its amyotrophic lateral sclerosis (ALS) treatment approved for use in the United States.
When seamlessly collaborating with partners on the same cloud-based safety solution, sponsors have real-time visibility and control while driving more efficient and faster processes. Easily scaling with more studies or data, modern pharmacovigilance (PV) applications are intuitive and designed for teams to work together globally.
Join this webinar to hear about strategies for developing patient-centric clinical outcome assessment and trial designs, methods for listening to patients throughout a trial and practical guidance on operationalizing a study for patient-centricity.